Claims
- 1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR50## in which (p,r,s) is selected from among (2,2,0), (2,1,1), (3,1,1), (2,1,0), and (3,1,0); and X represents a group ##STR51## in which A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.1 and the other is nitrogen or CR.sub.2, or A.sub.2 is oxygen or sulphur, A.sub.1 is CH and A.sub.3 is CR.sub.1, where R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1-2 alkyl, with the proviso that when r is 2, R.sub.1 and R.sub.2 are independently hydrogen or methyl.
- 2. A compound according to claim 1 wherein X is 1,2-oxazol-5-yl, 3-methyl-1,2-oxazol-5-yl, 1,3-oxazol-5-yl, 2-methyl-1,3-oxazol-5-yl, 2-ethyl-1, 3-oxazol-5-yl, furan-2-yl, furan-3-yl or 5-methyl-furan-2-yl.
- 3. A compound according to claim 1 wherein (p,r,s) is (2,2,1) or (2,1,1).
- 4. A compound of formula (1) according to claim 1 having two assymetric centres, in the exo configuration.
- 5. A compound selected from:
- (.+-.) 3-(1,2-Oxazol-5-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) 3-(Fur-2-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) 3-(5-Methyl-fur-2-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) exo-3-(Fur-2-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) exo-3-(5-Methyl-fur-2-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) 3-(3-Methyl-1,2-oxazol-5-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) 3-(2-Methyl-1,3-oxazol-5-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) exo-3-(2-Methyl-1,3-oxazol-5-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) endo-3-(2-Methyl-1,3-oxazol-5-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) exo-3-(3-Methyl-1,2-oxazol-5-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) 3-(Fur-3-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) 3-(1,3-Oxazol-5-yl)-1-azabicyclo[2.2.2]octane,
- (.+-.) exo-3-(1,3-Oxazol-5-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) endo-3-(1,3-Oxazol-5-yl)-1-azabicyclo[2.2.1]heptane,
- (.+-.) exo-3-(1,2-Oxazol-5-yl)-1-azabicyclo[2.2.1]heptane, and
- (.+-.) 3-(2-Ethyl-1,3-oxazol-5-yl)-1-azabicyclo[2.2.1]heptane, or a pharmaceutically acceptable salt thereof.
- 6. A pharmaceutical composition for the treatment or prophylaxis of dementia in humans comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 7. A method of treatment or prophylaxis of dementia in mammals, which comprises administering to the patient an effective amount of a compound of formula (I) as defined in claim 1.
Priority Claims (3)
Number |
Date |
Country |
Kind |
8729806 |
Dec 1987 |
GBX |
|
8812603 |
May 1988 |
GBX |
|
8824074 |
Oct 1988 |
GBX |
|
Parent Case Info
This application is a continuation of application Ser. No. 08/072,357, filed Jun. 3rd, 1993, now abandoned, which is a continuation of application Ser. No. 880,489, filed May 6th, 1992, now abandoned, which is a continuation of application Ser. No. 500,229, filed Mar. 27th, 1990, now abandoned, which is a continuation of application Ser. No. 287,466, filed Dec. 20th, 1988, now abandoned.
Foreign Referenced Citations (4)
Number |
Date |
Country |
307141 |
Mar 1989 |
EPX |
0307141 |
Mar 1989 |
EPX |
316718 |
May 1989 |
EPX |
0316718 |
May 1989 |
EPX |
Continuations (4)
|
Number |
Date |
Country |
Parent |
72357 |
Jun 1993 |
|
Parent |
880489 |
May 1992 |
|
Parent |
500229 |
Mar 1990 |
|
Parent |
287466 |
Dec 1988 |
|